Fortrea Partners with Medidata to Increase Diversity in Clinical Trials

Under this new agreement, Fortrea will leverage the capabilities of Medidata AI Intelligent Trials, including features such as study feasibility and diversity data.

Fortrea, a prominent global contract research organisation (CRO), has partnered with Medidata, a Dassault Systemes company and a leading provider of clinical trial solutions. The collaboration aims to utilise Medidata AI Intelligent Trials to enhance access to a diverse patient pool in Fortrea-conducted clinical trials.

This partnership builds upon the existing collaboration between the two companies, which involves Fortrea's use of Medidata Rave EDC—a sophisticated, secure EDC system for the capture and management of clinical trial site, patient, and lab data.

Under this new agreement, Fortrea will leverage the capabilities of Medidata AI Intelligent Trials, including features such as study feasibility and diversity data.

The partnership seeks to assist both emerging and large biopharma, as well as medical device and diagnostic companies, in achieving enrollment goals that reflect the populations most impacted by each disease or condition under study.

Mark Morais, COO and president of clinical services, Fortea, said, “We are thrilled to work with Medidata as part of Fortrea’s go-forward data strategy. Medidata’s data and interface capabilities will enhance our ability to seamlessly integrate diverse populations into the clinical trial process”

The US-based clinical development and patient access solution company, Fortrea is a transformative force in clinical trial research, design, and device development. The company partners with emerging and large biopharmaceutical, medical device and diagnostic companies to drive healthcare innovation that accelerates life-changing therapies to patients in need.

While founded in 1999, Medidata Solutions is an American technology company that develops and markets software as a service (SaaS) for clinical trials. Medidata’s customers include pharmaceutical, biotechnology, medical device, and diagnostic companies; academic and government institutions; contract research organisations; and other life sciences organisations around the world that develop and bring medical therapies and products to market. In December 2019, Medidata was acquired by Dassault Systèmes and now functions as a subsidiary.

Fareed Melhem, SVP, Medidata AI, said “Fortrea and Medidata share a commitment to advancing clinical trial research and this partnership is poised to reshape the landscape of diversity in clinical trials globally. Together, our solutions support customers in life sciences to accelerate study timelines and make the benefits of clinical therapies more accessible to a diverse spectrum of individuals.”

In another significant global update, Swedish-based Medtech company, SciBase partnered with Skin & Cancer Institute to advance AI-driven skin cancer detector - Nevisense in California.

Nevisense is an AI-based point-of-care system for the non-invasive evaluation of atypical pigmented lesions. It is the only FDA-approved technology available for early melanoma detection in the US. The new features include a streamlined and more efficient workflow to examine atypical pigmented lesions.